Deficiency of FRMD5 results in neurodevelopmental dysfunction and autistic-like behavior in mice
- PMID: 38228891
- DOI: 10.1038/s41380-024-02407-w
Deficiency of FRMD5 results in neurodevelopmental dysfunction and autistic-like behavior in mice
Abstract
The pathophysiology of autism spectrum disorders (ASDs) is causally linked to postsynaptic scaffolding proteins, as evidenced by numerous large-scale genomic studies [1, 2] and in vitro and in vivo neurobiological studies of mutations in animal models [3, 4]. However, due to the distinct phenotypic and genetic heterogeneity observed in ASD patients, individual mutation genes account for only a small proportion (<2%) of cases [1, 5]. Recently, a human genetic study revealed a correlation between de novo variants in FERM domain-containing-5 (FRMD5) and neurodevelopmental abnormalities [6]. In this study, we demonstrate that deficiency of the scaffolding protein FRMD5 leads to neurodevelopmental dysfunction and ASD-like behavior in mice. FRMD5 deficiency results in morphological abnormalities in neurons and synaptic dysfunction in mice. Frmd5-deficient mice display learning and memory dysfunction, impaired social function, and increased repetitive stereotyped behavior. Mechanistically, tandem mass tag (TMT)-labeled quantitative proteomics revealed that FRMD5 deletion affects the distribution of synaptic proteins involved in the pathological process of ASD. Collectively, our findings delineate the critical role of FRMD5 in neurodevelopment and ASD pathophysiology, suggesting potential therapeutic implications for the treatment of ASD.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
References
-
- Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. Lancet. 2018;392:508–20. https://doi.org/10.1016/S0140-6736(18)31129-2 . - DOI - PubMed - PMC
-
- Lord C, Bishop SL. Recent advances in autism research as reflected in DSM-5 criteria for autism spectrum disorder. Annu Rev Clin Psychol. 2015;11:53–70. https://doi.org/10.1146/annurev-clinpsy-032814-112745 . - DOI - PubMed
-
- Baribeau D, Anagnostou E. Novel treatments for autism spectrum disorder based on genomics and systems biology. Pharm Ther. 2022;230:107939 https://doi.org/10.1016/j.pharmthera.2021.107939 . - DOI
-
- Jiang C-C, Lin L-S, Long S, Ke X-Y, Fukunaga K, Lu Y-M, et al. Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications. Signal Transduct Target Ther. 2022;7:229 https://doi.org/10.1038/s41392-022-01081-0 . - DOI - PubMed - PMC
-
- Shaw KA, McArthur D, Hughes MM, Bakian AV, Lee L-C, Pettygrove S, et al. Progress and disparities in early identification of autism spectrum disorder: autism and developmental disabilities monitoring network, 2002-2016. J Am Acad Child Adolesc Psychiatry. 2022;61:905–14. https://doi.org/10.1016/j.jaac.2021.11.019 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
- 2021ZD0203204/Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology)
- 2022YFA1104003/Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology)
- 2017YFA0701302/Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology)
- 2022YFA1104003 and 2021YFC2501003/Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology)
- 82230094/National Natural Science Foundation of China (National Science Foundation of China)
LinkOut - more resources
Full Text Sources
Medical